[Therapeutic efficiency of an angiogenesis inhibitor, TNP-470, against carcinomatous peritonitis in rodents].
TNP-470, an analog of fumagillin, is one of the new angiogenesis inhibitors. Five days after an intraperitoneal inoculation of 10(7) cells of Walker 256 carcinosarcoma to SD rats, TNP-470 was injected intraperitoneally in the form of TNP aqueous solution or TNP-oil solution. Mean survival time of rats given TNP-oil solution or TNP aqueous solution was statistically prolonged, compared with that of the control rats. Our results showed that TNP-470 is an effective therapeutic drug for carcinomatous peritonitis.
Ozaki
K
K
First Dept. of Surgery, Kyoto Prefectural University of Medicine.
Takahashi
T
T
Hagiwara
A
A
Shimotsuma
M
M
Sakakura
C
C
Sasaki
S
S
Shirasu
M
M
Tsujimoto
H
H
Oyama
T
T
Sakakibara
T
T
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002279:Carcinoma 256, Walker / Q000150:complications*; D003510:Cyclohexanes; D007263:Infusions, Parenteral; D008297:Male; D008546:Melanoma, Experimental / Q000150:complications*; D051379:Mice; D008810:Mice, Inbred C57BL; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D010538:Peritonitis / Q000188:drug therapy* / Q000209:etiology; D051381:Rats; D012717:Sesquiterpenes / Q000627:therapeutic use*
D000903:Antibiotics, Antineoplastic; D003510:Cyclohexanes; D012717:Sesquiterpenes; D000077609:O-(Chloroacetylcarbamoyl)fumagillol